Pre-filled Syringe Presentation of BYOOVIZ®, Samsung Bioepis' Biosimilar to Lucentis (Ranibizumab), Gains European Approval

Group 1 - Samsung Bioepis' Byooviz PFS has received European approval, marking a significant milestone for the company in the biopharmaceutical sector [1] - This approval is expected to enhance Samsung Bioepis' position in the biosimilar market, particularly in Europe [1] - The company aims to leverage this approval to expand its product offerings and increase market share in the competitive landscape of biologics [1]